Abstract
Nerivio® (by Theranica Bio-Electronics Ltd, Tel Aviv, Israel) is a wireless, wearable, noninvasive, battery-operated, remote electrical neuromodulationdevice controlled by a smartphone application. It is USFDA authorized for the acute treatment of migraine with or without aura in people 12years and older in the US, and European Conformity (CE) marked for the same indication in the EU. The American Headache SocietyConsensus Statement recommends Nerivioas a tier 2 treatment for migraines. This review summarizes a series of five independent clinical trials and two real-world evidence studies that established safety, tolerabilityand efficacy of Nerivioin treating migraine attacks. It further provides up-to-date practical information on device usability. Based on findings of this review, Neriviooffers a safe and effective nonpharmacological alternative for acute treatment in patients with chronic (and nonchronic) migraine.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
